Profile
Home  /   Staff  /   Researcher Profiles  /  Prof. John Forbes  /  Research Publications

Prof. John Forbes

Work Phone (02) 4985 0113
Fax (02) 4960 1539
Email
Office 2.041, Nbn Telethon Mater Institute

Publications

For items published while at an institution other that the University of Newcastle, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Chapters In A Book (2 outputs)

Chapter in A1 Book (B1) (2 outputs)

Year Citation Link
2007 Forbes John Frederick, 'Antiestrogens', Endocrine Therapies in Breast Cancer, Oxford University Press, Oxford, 29-36 (2007) [B1]
2003 Forbes John Frederick, 'Breast cancer', Evidence-Based Oncology, BMJ, London, 429-464 (2003) [B1]

Journal Articles (74 outputs)

Refereed Article in a Scholarly Journal (C1) (64 outputs)

Year Citation Link
2012 Barrios C, Forbes John Frederick, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson J F R, 'The sequential use of endocrine treatment for advanced breast cancer: Where are we?', Annals of Oncology, 23 1378-1386 (2012) [C1]
2012 Bliss Judith M, Kilburn Lucy S, Coleman Robert E, Forbes John Frederick, Coates Alan S, Jones Stephen E, Jassem Jacek, Delozier Thierry, Andersen Jorn, Paridaens Robert, Van De Velde Cornelius J H, Lonning Per E, Morden James, Reise Justine, Cisar Laura, Menschik Thomas, Coombes R Charles, 'Disease-related outcomes with long-term follow-up: An updated analysis of the Intergroup Exemestane Study', Journal of Clinical Oncology, 30 709-717 (2012) [C1]
2012 Ewertz Marianne, Gray Kathryn P, Regan Meredith M, Ejlertsen Bent, Price Karen N, Thurlimann Beat, Bonnefoi Herve, Forbes John Frederick, Paridaens Robert J, Rabaglio Manuela, Gelber Richard D, Colleoni Marco, Lang Istvan, Smith Ian E, Coates Alan S, Goldhirsch Aron, Mouridsen Henning T, 'Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial', Journal of Clinical Oncology, 30 3967-3975 (2012) [C1]
2012 Karlsson P, Cole B F, Chua B H, Price K N, Lindtner J, Collins J P, Kovacs A, Thurlimann B, Crivellari D, Castiglione-Gertsch M, Forbes John Frederick, Gelber R D, Goldhirsch A, Gruber G, 'Patterns and risk factors for locoregional failures after mastectomy for breast cancer: An International Breast Cancer Study Group Report', Annals of Oncology, 23 2852-2858 (2012) [C1]
2012 Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes John Frederick, Howell A, Cuzick J, 'Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial', British Journal of Cancer, 107 230-233 (2012) [C1]
2012 Sestak Ivana, Harvie Michelle, Howell Anthony, Forbes John Frederick, Dowsett Mitch, Cuzick Jack, 'Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer', Breast Cancer Research and Treatment, 134 727-734 (2012) [C1]
2011 Colleoni Marco, Giobbie-Hurder Anita, Regan Meredith M, Thurlimann Beat, Mouridsen Henning, Mauriac Louis, Forbes John Frederick, Paridaens Robert, Lang Istvan, Smith Ian, Chirgwin Jacquie, Pienkowski Tadeusz, Wardley Andrew, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, 'Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study', Journal of Clinical Oncology, 29 1117-1124 (2011) [C1]
2011 Cuzick Jack, Decensi Andrea, Arun Banu, Brown Powell H, Castiglione Monica, Dunn Barbara, Forbes John Frederick, Glaus Agnes, Howell Anthony, Von Minckwitz Gunter, Vogel Victor, Zwierzina Heinz, 'Preventive therapy for breast cancer: A consensus statement', The Lancet Oncology, 12 496-503 (2011) [C1]
2011 Cuzick Jack, Dowsett Mitch, Pineda Silvia, Wale Christopher, Salter Janine, Quinn Emma, Zabaglo Lila, Mallon Elizabeth, Green Andrew R, Ellis Ian O, Howell Anthony, Buzdar Aman U, Forbes John Frederick, 'Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and comparison with the Genomic Health Recurrence Score in early breast cancer', Journal of Clinical Oncology, 29 4273-4278 (2011) [C1]
2011 Cuzick Jack, Sestak Ivanna, Pinder Sarah E, Ellis Ian O, Forsyth Sharon, Bundred Nigel J, Forbes John Frederick, Bishop Hugh, Fentiman Ian S, George William D, 'Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK/ANZ DCIS trial', The Lancet Oncology, 12 21-29 (2011) [C1]
2011 Cuzick Jack, Warwick Jane, Pinney Elizabeth, Duffy Stephen W, Cawthorn Simon, Howell Anthony, Forbes John Frederick, Warren Ruth M L, 'Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: A nested case-control study', Journal of the National Cancer Institute, 103 744-752 (2011) [C1]
2011 Dowsett Mitch, Salter Janine, Zabaglo Lila, Mallon Elizabeth, Howell Antony, Buzdar Aman U, Forbes John Frederick, Pineda S, Cuzick Jack, 'Predictive algorithms for adjuvant therapy: TransATAC', Steroids, 76 777-780 (2011) [C1] Nova
2011 Regan Meredith M, Neven Patrick, Giobbie-Hurder Anita, Goldhirsch Aron, Ejlertsen Bent, Mauriac Louis, Forbes John Frederick, Smith Ian, Lang Ian, Wardley Andrew, Rabaglio Manuela, Price Karen N, Gelber Richard D, Coates Alan S, Thurlimann Beat, 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up', Lancet Oncology, 12 1101-1108 (2011) [C1]
2011 Ring Alistair, Sestak Ivana, Baum Michael, Howell Anthony, Buzdar Aman, Dowsett Mitch, Forbes John Frederick, Cuzick Jack, 'Influence of comorbidities and age on risk of death without recurrence: A retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination Trial', Journal of Clinical Oncology, 29 4266-4272 (2011) [C1]
2011 Stockler Martin R, Harvey Vernon J, Francis Prudence A, Byrne Michael J, Ackland Stephen, Fitzharris Bernie, Van Hazel Guy, Wilcken Nicholas R C, Grimison Peter S, Nowak Anna K, Gainford M Corona, Fong Akiko, Paksec Lisa Anne, Sourjina Tatiana, Zannino Diana, Gebski Val, Simes R John, Forbes John Frederick, Coates Alan S, 'Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer', Journal of Clinical Oncology, 29 4498-4504 (2011) [C1]
2011 Tang Gong, Cuzick Jack, Costantino Joseph P, Dowsett Mitch, Forbes John Frederick, Crager Michael, Mamounas Eleftherios P, Shak Steven, Wolmark Norman, 'Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors', Journal of Clinical Oncology, 29 4365-7372 (2011) [C1]
2011 Toi Masakazu, Winer Eric P, Inamoto Takashi, Benson John R, Forbes John Frederick, Mitsumori Michihide, Robertson John F R, Sasano Hironobu, Von Minckwitz Gunter, Yamauchi Akira, Klimberg V Suzanne, 'Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto Consensus Conference', Annals of Surgical Oncology, 18 2885-2892 (2011) [C1] Nova
2011 Valero Vicente, Forbes John Frederick, Pegram Mark D, Pienkowski Tadeusz, Eiermann Wolfgang, Von Minckwitz Gunter, Roche Henri, Martin Miguel, Crown John, Mackey John R, Fumoleau Pierre, Rolski Janusz, Mrsic-Krmpotic Zrinka, Jagiello-Gruszfeld Agnieszka, Riva Alessandro, Buyse Marc, Taupin Henry, Sauter Guido, Press Michael F, Slamon Dennis J, 'Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 Study): Two highly active the rapeutic regimens', Journal of Clinical Oncology, 29 149-156 (2011) [C1]
2011 Viale G, Regan M M, Dell'Orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes John Frederick, Paridaens R J, Colleoni M, Lang I, Thurlimann B, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, 'Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial', Annals of Oncology, 22 2201-2207 (2011) [C1]
2010 Cuzick Jack, Sestak Ivana, Baum Michael, Buzdar Aman, Howell Anthony, Dowsett Mitch, Forbes John Frederick, 'Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial', The Lancet Oncology, 11 1135 - 1141 (2010) [C1] Nova
2010 Dowsett Mitch, Cuzick Jack, Ingle Jim, Coates Alan, Forbes John Frederick, Bliss Judith, Buyse Marc, Baum Michael, Buzdar Aman, Colleoni Marco, Coombes Charles, Snowdon Claire, Gnant Michael, Jakesz Raimund, Kaufmann Manfred, Boccardo Francesco, Godwin Jon, Davies Christina, Peto Richard, 'Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus Tamoxifen', Journal of Clinical Oncology, 28 509-518 (2010) [C1] Nova
2010 Dowsett Mitch, Cuzick Jack, Wale Christopher, Forbes John Frederick, Mallon Elizabeth A, Salter Janine, Quinn Emma, Dunbier Anita, Baum Michael, Buzdar Aman, Howell Anthony, Bugarini Roberto, Baehner Frederick L, Shak Steven, 'Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC Study', Journal of Clinical Oncology, 28 1829-1834 (2010) [C1] Nova
2010 Pinder S E, Duggan C, Ellis I O, Cuzick J, Forbes John Frederick, Bishop H, Fentiman I S, George W D, 'A new pathological system for grading DCIS with improved prediction of local recurrence: Results from the UKCCCR/ANZ DCIS Trial', British Journal of Cancer, 103 94-100 (2010) [C1] Nova
2010 Sestak Ivana, Distler Wolfgang, Forbes John Frederick, Dowsett Mitch, Howell Anthony, Cuzick Jack, 'Effect of body mass index on recurrences in Tamoxifen and Anastrozole treated women: An exploratory analysis from the ATAC trial', Journal of Clinical Oncology, 28 3411-3415 (2010) [C1] Nova
2009 Green M D, Francis P A, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Fong A, Basser R, Forbes John Frederick, 'Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer', Annals of Oncology, 20 1813-1817 (2009) [C1] Nova
2009 Mouridsen Henning, Giobbie-Hurder Anita, Goldhirsch Aron, Thurlimann Beat, Paridaens Robert, Smith Ian, Mauriac Louis, Forbes John Frederick, Price Karen N, Regan Meredith M, Gelber Richard D, Coates Alan S, 'Letrozole therapy alone or in sequence with Tamoxifen in women with breast cancer', New England Journal of Medicine, 361 766-776 (2009) [C1] Nova
2009 Pagani Olivia, Gelber Shari, Simoncini Edda, Castiglione-Gertsch Monica, Price Karen N, Gelber Richard D, Holmberg Stig B, Crivellari Diana, Collins John, Lindtner Jurij, Thurlimann Beat, Fey Martin F, Murray Elizabeth, Forbes John Frederick, Coates Alan S, Goldhirsch Aron, 'Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93', Breast Cancer Research and Treatment, 116 491-500 (2009) [C1] Nova
2009 Rabaglio M, Sun Z, Price K N, Castiglione-Gertsch M, Hawle H, Thurlimann B, Mouridsen H, Campone M, Forbes John Frederick, Paridaens R J, Colleoni M, Pienkowski T, Nogaret J M, Lang I, Smith I, Gelber R D, Goldhirsch A, Coates A S, 'Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial', Annals of Oncology, 20 1489-1498 (2009) [C1] Nova
2009 Thurlimann Beat, Price Karen N, Gelber Richard D, Holmberg Stig B, Crivellari Diana, Colleoni Marco, Collins John, Forbes John Frederick, Castiglione-Gertsch Monica, Coates Alan S, Goldhirsch Aron, 'Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93', Breast Cancer Research and Treatment, 113 137-144 (2009) [C1] Nova
2008 Atac Trialists' Group, Forbes John Frederick, 'Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial', Lancet Oncology, 9 45-53 (2008) [C1] Nova
2008 Bernhard J, Zahrieh D, Zhang J J, Martinelli G, Basser R, Hurny C, Forbes John Frederick, Aebi S, Yeo W, Thurlimann B, Green M D, Colleoni M, Gelber R D, Castiglione-Gertsch M, Price K N, Goldhirsch A, Coates A S, 'Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer', British Journal of Cancer, 98 25-33 (2008) [C1] Nova
2008 Crivellari Diana, Sun Zhuoxin, Coates Alan S, Price Karen N, Thurlimann Beat, Mouridsen Henning, Mauriac Louis, Forbes John Frederick, Paridaens Robert J, Castiglione-Gertsch Monica, Gelber Richard D, Colleoni Marco, Lang Istvan, Del Mastro Lucia, Gladieff Laurence, Rabaglio Manuela, Smith Ian E, Chirgwin Jacquie H, Goldhirsch Aron, 'Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1-98 trial', Journal of Clinical Oncology, 26 1972-1979 (2008) [C1] Nova
2008 Dowsett Mitch, Allred Craig, Knox Jill, Quinn Emma, Salter Janine, Wale Chris, Cuzick Jack, Houghton Joan, Williams Norman, Mallon Elizabeth, Bishop Hugh, Ellis Ian, Larsimont Danis, Sasano Hironobu, Carder Pauline, Cussac Antonio L, Knox Fiona, Speirs Valerie, Forbes John Frederick, Buzdar Aman, 'Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial', Journal of Clinical Oncology, 26 1059-1065 (2008) [C1] Nova
2008 Gao Jinnan, Warren Ruth, Warren-Forward Helen, Forbes John Frederick, 'Reproducibility of visual assessment on mammographic density', Breast Cancer Research and Treatment, 108 121-127 (2008) [C1] Nova
2008 Juraskova I, Butow P, Lopez A, Seccombe Margaret Ann, Coates A, Boyle F, McCarthy N, Reaby L, Forbes John Frederick, 'Improving informed consent: Pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS)', Health Expectations, 11 252-262 (2008) [C1] Nova
2008 Leyland-Jones Brian R, Ambrosone Christine B, Bartlett John, Ellis Matthew J C, Enos Rebecca A, Raji Adekunle, Pins Michael R, Zujewski Jo Anne, Hewitt Stephen M, Forbes John Frederick, Abramovitz Mark, Braga Sofia, Cardoso Fatima, Harbeck Nadia, Denkert Carsten, Jewell Scott D, 'Recommendations for collection and handling of specimens from group breast cancer clinical trials', Journal of Clinical Oncology, 26 5638-5644 (2008) [C1] Nova
2008 Sestak Ivana, Cuzick Jack, Sapunar Francisco, Eastell Richard, Forbes John Frederick, Bianco Angelo R, Buzdar Aman U, 'Risk factors for joint symptoms in patients enrolled in the ATAC trial: A retrospective, exploratory analysis', Lancet Oncology, 9 866-872 (2008) [C1] Nova
2007 Bernhard Jurg, Zahrieh David, Castiglione-Gertsch Monica, Hurny Christoph, Gelber Richard D, Forbes John Frederick, Murray Elizabeth, Collins John, Aebi Stefan, Thurlimann Beat, Price Karen N, Goldhirsch Aron, Coates Alan S, 'Adjuvant chemotherapy followed by goserelin compared with either modality alone: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--The International Breast Cancer Study Group Trial VIII', Journal of Clinical Oncology, 25 263-270 (2007) [C1]
2007 Coates A S, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes John Frederick, Paridaens R, Castiglione-Gertsch M, Gelber R D, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret J M, Pienkowski T, Wardley A, Jakobsen E H, Price K N, Goldhirsch A, 'Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98', Journal of Clinical Oncology, 25 486-492 (2007) [C1]
2007 Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S, Jassem J, Van De Velde C, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates A, Bajetta E, Holmberg S, Dodwell D, Mickiewicz E, Andersen J, Lonning P, Cocconi G, Forbes John Frederick, Castiglione M, Stuart N, Stewart A, Fallowfield L, Bertelli G, Hall E, Bogle R, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss J, 'Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial', Lancet, 369 559-570 (2007) [C1]
2007 Cuzick J, Forbes John Frederick, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, 'Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial', Journal of the National Cancer Institute, 99 272-282 (2007) [C1]
2007 Easton D F, Search Collaborators Including, Forbes John Frederick, 'Genome-wide association study identifies novel breast cancer susceptibility loci', Nature, 447 1087-1093 (2007) [C1] Nova
2007 Karlsson P, Cole B F, Price K N, Coates A S, Castiglione-Gertsch M, Gusterson B A, Murray E, Linditner J, Collins J P, Holmberg S B, Fey M F, Thurliumann B, Crivellari D, Forbes John Frederick, Gelber R D, Goldhirsch A, Wallgren A, 'The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer', Journal of Clinical Oncology, 25 2019-2026 (2007) [C1]
2007 Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes John Frederick, Thurlimann B, Paridaens R, Monnier A, Lang I, Wardley A, Nogaret J M, Gelber R D, Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, 'Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial', Annals of Oncology, 18 859-867 (2007) [C1]
2007 Mouridsen Henning, Keshaviah Aparna, Coates Alan S, Rabaglio Manuela, Castiglione-Gertsch Monica, Sun Zhuoxin, Thurlimann Beat, Mauriac Louis, Forbes John Frederick, Paridaens Robert, Gelber Richard D, Colleoni Marco, Smith Ian, Price Karen N, Goldhirsch Aron, 'Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 Trial', Journal of Clinical Oncology, 25 5715-5722 (2007) [C1]
2007 Santen R J, Boyd N F, Chlebowski R T, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes John Frederick, Key T, Hankinson S E, Howell A, Ingle J, 'Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model', Endocrine-Related Cancer, 14 169-187 (2007) [C1]
2007 The International Breast Cancer Study Group, Forbes John Frederick, 'Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93', Annals of Oncology, 18 1177-1184 (2007) [C1]
2006 Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes John Frederick, Jonat W, Ravdin P, 'Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer', Current Medical Research and Opinion, 22 1575-1585 (2006) [C1]
2006 Forbes John Frederick, 'The Use of Early Adjuvant Aromatase Inhibitor Therapy: Contributions From the BIG 1-98 Letrozole Trial', Seminars in Oncology, 33 S2-S7 (2006) [C1]
2006 Rudenstam Carl-Magnus, Forbes John Frederick, Crivellari Diana, Castiglione-Gertsch Monica, Goldhirsch Aron, Gelber Richard D, Coates Alan S, 'Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older patients With Breat Cancer: First Results of International Breast Cancer Study Group Trial 10-93', journal of Clinical Oncology, 24 337-344 (2006) [C1]
2006 Sestak Ivana, Kealy Roseann, Edwards Robert, Forbes John Frederick, Cuziack Jack, 'Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms', Journal of Clinical Oncology, 24 3991-3996 (2006) [C1]
2005 FORBES J F, EARLY BREAST CANCER TRIALISTS' C, 'Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials', Lancet, 366 2087-2106 (2005) [C1]
2005 Colleoni M, Li S, Gelber R D, Coates A S, Castiglione-Gertsch M, Price K N, Lindtner J, Rudenstam C M, Crivellari D, Collins J, Pagani O, Simoncini E, Thurlimann B, Murray E, Forbes John Frederick, Erzen D, Holmberg S, Veronesi A, Goldhirsch A, 'Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor', Annals of Oncology, 16 716-725 (2005) [C1]
2005 Forbes John Frederick, 'Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-year Survival: an Overview of the Randomized Trials', The Lancet, 365 1687-1717 (2005) [C1]
2005 Forbes John Frederick, 'Letrozole vs. Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women with Receptor-Positive Breast Cancer. BIG 1-98: A Prospective Randomized Double-Blind Phase III Study', The Breast, 14 - (2005) [C1]
2005 Thurlimann B, Kehsaviah A, Coates A, Mouridsen H, Mauriac L, Forbes John Frederick, Paridaens R, Castiglione-Gertsch M, Gelber R, Rabaglio M, Smith I, Wardly A, Price K, Goldhirsch A, 'A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer', New England Journal of Medicine, 353 2747-2758 (2005) [C1]
2004 Bernhard J, Zahrieh D, Coates A S, Gelber R D, Castiglione-Gertsch M, Murray E, Forbes John Frederick, Perey L, Collins J, Snyder R, Rudenstam C M, Crivellari D, Veronesi A, Thurlimann B, Fey M F, Price K N, Goldhirsch A, Hurny C, 'Quantifying trade-offs: Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer', British Journal of Cancer, 91 1893-1901 (2004) [C1]
2003 Aapro Matti S, Forbes John Frederick, 'Three years' follow-up from the ATAC trial is sufficient to change clinical practice: A debate', Breast Cancer Research and Treatment, 80 3-11 (2003) [C1]
2003 Cuzick J, Powles T, Veronesi U, Forbes John Frederick, Edwards R, Ashley S, Boyle P, 'Overview of the main outcomes in breast-cancer prevention trials', The Lancet, 361 296-300 (2003) [C1]
2003 Wallgren A, Bonetti M, Gelber Rd, Goldhirsch M, Castiglione-Gertsch Sb, Holmberg J, Lindtner B, Thurlimann M, Fey Id, Werner Id, Forbes John Frederick, Price K, Coates As, Collins J, 'Risk factors for Locoregional Recurrence Among Breast Cancer Patients: Results from international breast cancer study group I through VII', Journal of Clinical Oncology, 21 1205-1213 (2003) [C1]
2002 Forbes John Frederick, Gradishar Wj, Ravdin Pm, 'Choosing between endocrine therapy and chemotherapy - or is there a role for combination therapy?', Breast Cancer Research and Treatment, 75 S37-S44 (2002) [C1]
2001 Thurlimann B, Price Kn, Castiglione M, Coates As, Goldhirsch A, Gelber Rd, Forbes John Frederick, Holmberg S, Veronesi A, Bernhard J, Zahrieh D, 'Randomized controlled trial of ovarian function suppression plux tamoxifen verses the same endocrine therapy plus chemotherapy: is chemotherapynecessary for premonopausalwomen withnonde-positive, endocrine-responsive breast cancer? First results of I ntern', The Breast, 10(Supplement3) 130-8 (2001) [C1]
2000 Colleoni M, O'Neill A, Goldhirsch A, Gelber Rd, Bonetti M, Thurlimann B, Price Kn, Castiglione-Gertsch M, Coates As, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes John Frederick, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam C-M, 'Identifying breast cancer patients at high risk for bone metastases', Journal of Clinical Oncology, 18 (23) 3925-3935 (2000) [C1]
2000 Crivellari D, Bonetti M, Gastiglione-Gertsch M, Gelber Rd, Rudenstam C-M, Thurlimann B, Price Kn, Coates As, Hurny C, Bernhard J, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes John Frederick, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A, 'Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluoruoracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII', Journal of Clinical Oncology, 18 (7) 1412-22 (2000) [C1]
Show 61 more

Non Refereed Article in a Scholarly Journal (C2) (3 outputs)

Year Citation Link
2012 Toi Masakazu, Benson John R, Winer Eric P, Forbes John Frederick, Von Minckwitz Gunter, Golshan Mehra, Robertson John F R, Sasano Hironobu, Cole Bernard F, Chow Louis W C, Pegram Mark D, Han Wonshik, Huang Chiun-Sheng, Ikeda Tadashi, Kanao Shotaro, Lee Eun-Sook, Noguchi Shinzaburo, Ohno Shinji, Partridge Ann H, Rouzier Roman, Tozaki Mitsuhiro, Sugie Tomoharu, Yamauchi Akira, Inamoto Takashi, 'Preoperative systemic therapy in locoregional management of early breast cancer: Highlights from the Kyoto Breast Cancer Consensus Conference', Breast Cancer Research and Treatment, 136 919-926 (2012) [C2]
2011 Loi Sherene, Symmans W Fraser, Bartlett John M S, Fumagalli Debora, Van'T Veer Laura, Forbes John Frederick, Bedard Philippe, Denkert Carsten, Zujewski Joanne, Viale Giuseppe, Pusztai Lajos, Esserman Laura J, Leyland-Jones Brian R, 'Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: Timing and specimen types', The Lancet Oncology, 12 1162-1168 (2011) [C2]
2005 Forbes John Frederick, Cuzick Jack, 'Systemic Adjuvant Therapies for Early Breast Cancer: 15-year Results for Recurrence and Survival', Medical Journal of Australia, 183 447-448 (2005) [C2]

Non Refereed Article in a Professional Journal (C3) (5 outputs)

Year Citation Link
2011 Cuzick Jack, Sestak Ivana, Baum Michael, Buzdar Aman, Howell Anthony, Dowsett Mitch, Forbes John Frederick, '10-year analysis of the ATAC trial: Wrong conclusion? - Authors' reply', The Lancet Oncology, 12 217 (2011) [C3]
2007 Juraskova I, Butow P, Lopez A L, Seccombe Margaret Ann, Boyle F, McCarthy N, Forbes John Frederick, 'Improving informed consent in clinical trials: Successful piloting of a decision aid', Journal of Clinical Oncology, 25 1443-1444 (2007) [C3]
2006 Cuzick J, Forbes John Frederick, Howell A, 'Re: Tamoxifen for the prevention of breast cancer: Current status of the national surgical adjuvant breast and bowel project P-1 study (Letter)', Journal of the National Cancer Institute, 98 643 (2006) [C3]
2005 Cuzick J, Howell A, Forbes John Frederick, 'Early stopping of clinical trials (Commentary)', Breast Cancer Research, 7 181-183 (2005) [C3]
2005 Forbes John Frederick, 'Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial After Completion of 5 years' Adjuvant Treatment for Breast Cancer', The Lancet, 365 60-62 (2005) [C3]
Show 2 more

Letter or Note (C4) (1 outputs)

Year Citation Link
2003 Cuzick J, Forbes John Frederick, Howell A, 'Tamoxifen for breast-cancer prevention', Lancet, 361 178 (2003) [C4]

Other Refereed Contribution to a Scholarly Journal (C5) (1 outputs)

Year Citation Link
2005 Cuzick Jack, Howell Anthony, Forbes John Frederick, 'Early Stopping of Clinical Trials', Breast Cancer Research, 7 181-183 (2005) [C5]

Conference Publication (23 outputs)

Extract of Paper (E3) (23 outputs)

Year Citation Link
2011 Kiejda Kelly Anne, Forbes John Frederick, Braye Stephen Geoffrey, Scott Rodney, 'MicroRNA expression profiling in triple-negative breast cancer', Keystone Symposia on Mollecular and Cellular Biology: MicroRNAs and Non-coding RNAs and Cancer, Banff, AL (2011) [E3]
2011 Kiejda Kelly Anne, Forbes John Frederick, Hope Tina L, Braye Stephen G, Scott Rodney, 'Differential expression of miRNAs in triple-negative breast cancer', AMATA Conference Canberra 2011 Handbook, Canberra, ACT (2011) [E3]
2011 Singh S, Cuzick J, Blake G M, Mesher D, Patel R, Truscott J, Coleman R, Howell A, Forbes John Frederick, Eastell R, 'One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study', Bone, Sheffield, UK (2011) [E3]
2010 Kiejda Kelly Anne, Forbes John Frederick, Braye Stephen Geoffrey, Scott Rodney, 'The relationship between p53 isofor and estrogen receptor-alpha expression in breast cancer', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2010 Wong-Brown Michelle, Bowden Nikola Ann, Forbes John Frederick, Braye Stephen Geoffrey, Scott Rodney, 'Microsatellite instability (I) in breast tumours', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2009 Bliss J, Kilburn L, Coleman R, Forbes John Frederick, Coates A, Jones S, Jassem J, Delozier T, Andersen J, Paridaens R, Coombes R, 'Disease related outcome with long term follow-up: An updated analysis of the Intergroup Exemestane Study (IES)', Cancer Research, San Antonio, TX (2009) [E3]
2009 Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes John Frederick, 'Prognostic value of a combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and comparison with the GHI Recurrence Score: Results from TransATAC', Cancer Research, San Antonio, TX (2009) [E3]
2009 Cuzick J, Sestak I, Pinder S, Ellis I, Hackshaw A, Bundred N, Forbes John Frederick, Bishop H, Fentiman I, George W, 'Beneficial effect of tamoxifen for women with DCIS: Long-term results from the UK/ANZ DCIS Trial in women with locally excised DCIS', Cancer Research, San Antonio, TX (2009) [E3]
2009 Gardner H, Nuciforo P, Liu W, Lee B, Rheinhardt J, Barrett C, Linnartz R, Dugan M, Eiermann W, Pienkowski T, Martin M, Robert N, Forbes John Frederick, Buyse M, Finn R, Lindsay M, Slamon D, Press M, 'PI3 kinase pathway analysis in tissue microarrays using laser capture microdissection and immunohistochemistry', Cancer Research, San Antonio, TX (2009) [E3]
2009 Howell A, Forbes John Frederick, Cuzick J, Atac Investigators, 'Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population', Breast, St Gallen, Switzerland (2009) [E3]
2009 Juraskova I, Butow P, Smith B, Seccombe Margaret Ann, Coates A, Boyle F M, McCarthy N, Reaby L, Forbes John Frederick, 'Improving informed consent to prevention clinical trials: A randomised controlled trial of a decision aid for women invited to participate in IBIS-II', Asia-Pacific Journal of Clinical Oncology, Gold Coast, QLD (2009) [E3]
2009 Sestak I, Distler W, Forbes John Frederick, Howell A, Cuzick J, 'Effect of body mass index on recurrence in hormone receptor positive early breast cancer: A retrospective exploratory analysis from the ATAC Trial', Cancer Research, San Antonio, TX (2009) [E3]
2008 Forbes John Frederick, Cuzick J, Buzdar A, Howell A, Baum M, 'ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion', Breast Cancer Research and Treatment, San Antonio, TX (2008) [E3]
2008 Grimison P S, Australian New Zealand Breast Cancer Trials Group, Coates A S, Forbes John Frederick, Cuzick J, Furnival C, Craft P S, Snyder R D, Thornton R M, Lindsay Dianne Frances, Simes R J, 'Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1)', Journal of Clinical Oncology, Chicago, ILL (2008) [E3]
2008 Sestak I, Forbes John Frederick, Edwards R, Howell A, Cuzick J, 'Timing and severity of prominent side effects of anastrozole and tamoxifen', EJC Supplements, Berlin, Germany (2008) [E3]
2007 Forbes John Frederick, Cuzick J, Buzdar A, Howell A, Baum M, 'ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion', Breast Cancer Research and Treatment, San Antonio, TX. (2007) [E3]
2007 Juraskova I, Butow P, Lopez A L, Seccombe M, Smith B, Coates A, Boyle F, McCarthy N, Reaby L, Forbes John Frederick, 'Improving informed consent in clinical trials: A randomised controlled trial of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II)', Breast Cancer Research and Treatment, San Antonio, TX. (2007) [E3]
2007 Pienkowski T, Pegram M, Forbes John Frederick, Valero V, Eiermann W, Von Minckwitz G, Martin M, Crowns J, 'BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)', European Journal of Cancer Supplements (ECCO 14 Abstract Book), Barcelona, Spain (2007) [E3]
2006 Finn R S, Dering J, Ginther C, Press M, Forbes John Frederick, Mackey J, French T, South M, Rupin M, Slamon D J, 'ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies (oral presentation)', Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I., Atlanta, Georgia (2006) [E3]
2006 Forbes John Frederick, Pienkowski T, Valero V, Eiermann W, Von Minckwitz G, Martin M, Smylie M, Crown J, Noel N, Pegram M, 'BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC)', Journal of Clinical Oncology (Vol 24, No 18S (June 20 Supplement), 2006: LBA516): 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Atlanta, Georgia (2006) [E3]
2004 Thompson Jennifer Dee, Warren-Forward Helen, Bennett M, Lai M K, Brown R L, Moran S M, Forbes John Frederick, 'Step one of a feasibility study into the reduction of recall rates in screening mammography', Australian Institute of Radiography 1st Annual Scientific Meeting of Medical Imaging and Radiation Therapy, Cairns, Australia (2004) [E3]
2000 Ackland Sp, Gebski V, Wilson A, Green M, Hornery Sj, Dhillon H, Levi Ja, Van Hazel G, Simes Rj, Forbes John Frederick, Coates As, 'High Dose Epirubicin & Cyclophosphamide (HDEC) with Filgrastim versus Standard Dose (SDEC) in Advanced Breast Cancer - A Quality of Life Study by the ANZ Breast Cancer Trials Group', Proceedings of the Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, USA (2000) [E3]
2000 Castiglione-Gertsch M, Price Kn, Nasi Ml, Lindtner J, Erzen D, Crivellari D, Veronesi A, Fey M, Pagani O, Collins J, Forbes John Frederick, Rudenstam C-M, 'Is the addition of Adjuvant Chemotherapy Always Necessary in Node Negative (N-) Postmenopausal Breast Cancer Patients (Pts) Who Receive Tamoxifen (TAM)?: First Results of IBCSG Trial IX', Proceedings of the Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, USA (2000) [E3]
Show 20 more